onclive· 2mo ago
save<![CDATA[FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer]]>
May 15, 2026read original ↗
<![CDATA[The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.]]>
The original article is no longer reachable from this URL.
read full article on onclive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that